BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

PHASE3CompletedINTERVENTIONAL
Enrollment

550

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 29, 2020

Study Completion Date

February 28, 2022

Conditions
Allogeneic Hematopoietic Stem Cell TransplantationBusulfanTotal Body IrradiationAcute Lymphocytic Leukemia
Interventions
DRUG

Busulfan (BU)

Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

DRUG

Cyclophosphamide (CY)

Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

RADIATION

Total Body Irradiation (TBI)

Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.

Trial Locations (1)

510515

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Guangzhou First People's Hospital

OTHER

collaborator

Zhujiang Hospital

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

The Seventh Affiliated Hospital of Sun Yat-sen University

OTHER

collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Guangdong Second Provincial General Hospital

OTHER

collaborator

The Affiliated Hospital of Qingdao University

OTHER

collaborator

First People's Hospital of Chenzhou

OTHER

collaborator

Guangzhou Panyu Central Hospital

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT02670252 - BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT | Biotech Hunter | Biotech Hunter